Scarica l'app Stockscreener
1.88
6.00%
-0.12
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
Candel Therapeutics Prostate Cancer Therapy Shows Promise - Yahoo Finance
Candel Therapeutics stock up 172% after Phase III prostate cancer success - Yahoo Finance
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial - Yahoo Finance
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - The Eastern Progress Online
Intensity Therapeutics stock hits 52-week low at $2.46 By Investing.com - Investing.com Canada
Intensity Therapeutics stock hits 52-week low at $2.46 - Investing.com
The Benchmark Company Announces Upcoming Discovery One-on-One Investor Conference - The Manila Times
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy - Yahoo Finance
TG Therapeutics to Participate in the Evercore HealthCONx Conference - Yahoo Finance
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Intensity Therapeutics Selected for Oral Podium Presentation in - GuruFocus.com
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Jeanette Fritsch Expands SIMPLY-HEALTH Platform to Offer Comprehensive Menopause Solutions for Midlife Professionals - Yahoo Finance
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO - AlphaStreet
Intensity Therapeutics secures $3 million in stock offering By Investing.com - Investing.com South Africa
Medical supplies giant Medline reportedly eyeing $5B IPO in 2025 - MSN
Intensity Therapeutics secures $3 million in stock offering - Investing.com India
Shelton-based Intensity Therapeutics gains $3M investment - Hartford Business Journal
H2G Green Limited Launches Major Rights Issue - MSN
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - Yahoo Finance
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease - Yahoo Finance
Intensity reports promising sarcoma treatment results - Investing.com
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at - StreetInsider.com
Intensity reports promising sarcoma treatment results By Investing.com - Investing.com UK
Intensity Therapeutics' Cancer Drug Triples Survival Time in Phase 1/2 Sarcoma Trial | INTS Stock News - StockTitan
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - PR Newswire
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024 - Yahoo Finance
Q&A: New cancer medication to treat refractory solid tumours - Digital Journal
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis - Yahoo Finance
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
3 US Penny Stocks With Market Caps Under $200M To Watch - Simply Wall St
Wednesday, November 13, 2024 - The Auto Channel
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke - Yahoo Finance
AstraZeneca Expands U.S. Investment Plan - MSN
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Yahoo Finance
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting - The Malaysian Reserve
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - Quantisnow
Stem Cell Therapy Market Analysis Report 2024-2029: iPSC Technology and Personalized Medicine Trends Drive Growth - Yahoo Finance
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - The Manila Times
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting - Yahoo Finance
Red Roof® Partners with St. Jude Children's Research Hospital® this Holiday Season to Help Defeat Childhood Cancer - Yahoo Finance
INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cydcor Unites for Breast Cancer Awareness Month, Embodying "People Helping People" Culture - Yahoo Finance
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):